Key Stats
- Current price: ~$26
- Q1 FY2026 revenue: $2.5B, up 5.4% YoY (reported); up 1.9% constant currency
- Q1 FY2026 non-GAAP EPS: $2.61
- Q1 FY2026 adjusted EBITDA: $348M; EBITDA margin: 13.9%
- Q2 FY2026 revenue guidance: $2.46B–$2.49B
- Q2 FY2026 non-GAAP EPS guidance: $2.57–$2.69
- Full-year FY2026 guidance: unchanged
- TIKR model price target: ~$33
- Implied upside over ~5 years: ~26%
Concentrix Stock Delivered In-Line Results — The Margin Recovery Is Still Ahead
Concentrix stock (CNXC) investors got an in-line quarter: Concentrix Corporation reported Q1 FY2026 revenue of $2.5B, up 5.4% year over year on a reported basis but only 1.9% in constant currency, alongside non-GAAP EPS of $2.61, both landing within the guidance range issued in January, according to Andre Valentine, Chief Financial Officer, on the Q1 2026 earnings call.
Banking and financial services led vertical performance, with revenue up 13% year over year in the quarter, according to Valentine on the Q1 2026 earnings call.
Retail, travel, and e-commerce contributed 6% constant currency growth, driven primarily by travel and e-commerce clients, while media and communications grew 3%.
Technology and consumer electronics and healthcare each declined roughly 6% in constant currency: the tech vertical was hit by a combination of underlying volume softness and shore-mix shift, while healthcare was pressured by Medicare membership changes and reduced Affordable Care Act participation among clients, according to Valentine on the Q1 2026 earnings call.
Non-GAAP operating income came in at $295M at the midpoint of guidance, with a non-GAAP operating margin of 11.8%.
CEO Chris Caldwell noted that signed annual contract value for AI-inclusive solutions more than doubled quarter over quarter and the company closed close to 60 enterprise iX Suite deals in Q1, including its largest iX Hero contracts to date with two Fortune 50 companies.
For Q2 FY2026, Concentrix guided revenue of $2.46B–$2.49B and non-GAAP EPS of $2.57–$2.69, with full-year guidance left unchanged.
Restructuring charges in Q1 and Q2 are expected to generate approximately $40M in annualized savings, with management guiding to sequential profitability growth in the second half of FY2026.
The company returned approximately $65M to shareholders in Q1, including $42M in share repurchases at an average price of approximately $40 and $23M in dividends.
Concentrix Stock Financials: Margin Compression Persists as the Recovery Setup Takes Shape
The income statement tells a consistent story across the last several quarters: operating margins are running below historical norms as transformation investments and shore-mix headwinds absorb capacity ahead of the revenue ramp.
Gross margin came in at 34.0% in the February 2026 quarter, down from 35.1% in May 2025 and compressing steadily from the 36.0%–36.2% range posted in mid-2024.
GAAP operating income was $160M in Q1 FY2026, down from $190M in the prior-year February 2025 quarter, with operating margin contracting to 6.2% from 7.9%.
The November 2024 quarter showed a more severe dip, with operating income falling to $40M and operating margin compressing to 1.6%, before recovering to $190M and 7.9% in February 2025.
The current quarter’s 6.2% GAAP operating margin sits below the 6.7%–6.8% range posted across May–August 2025, pointing to continued rather than improving pressure.
Excess physical capacity is contributing 20 to 40 basis points of margin drag, according to Valentine on the Q1 2026 earnings call, with management expecting that headwind to reverse as offshore revenue ramps through the second half.
What Does the Valuation Model Say?
The TIKR model prices Concentrix stock at approximately $33, implying roughly 27% upside from the current price of approximately $26.
The model assumes a revenue CAGR of 1.8% and a net income margin of 7.2% in the mid case, with EPS growth CAGR of 4.1% through the forecast period.
The Q1 result does not move the investment thesis in either direction: the quarter was exactly what management guided, which is consistency rather than a catalyst.
The investment case hinges almost entirely on whether the promised H2 margin recovery arrives on schedule; this quarter confirmed the setup but offered no early evidence of the turn.
Concentrix Corporation stock trades at a meaningful discount to model value, but closing that gap depends on a margin recovery that has not yet shown up in reported figures.
What Has to Go Right
- Non-GAAP operating margin needs to expand from 11.8% in Q1 toward the 13%-plus range in Q4, consistent with management’s full-year guidance and historical margins from FY2022–FY2024
- The $100M–$150M of additional second-half revenue cited by Valentine on the Q1 2026 earnings call must come online and absorb the excess physical capacity currently dragging margins by 20 to 40 basis points
- iX Hero ARR needs to reach or exceed $100M by fiscal year-end from $60M at the end of Q4 FY2025, with accretive margins replacing the current onboarding-phase compression on new AI contracts
- Banking and financial services must sustain the high-single-digit to low-double-digit constant currency growth trajectory that powered the vertical’s 13% Q1 performance
What Could Still Go Wrong
- Healthcare revenue, under pressure from Medicare membership declines and reduced ACA participation, is not expected to return to growth for several quarters, according to Valentine on the Q1 2026 earnings call
- Shore-mix headwinds are estimated at roughly 2 points of annual revenue drag; offshore capacity only becomes accretive once programs reach full run-rate, and that timeline can slip
- Geopolitical caution is already embedded in Q2 guidance conservatism; broader client hesitation or escalation beyond the company’s approximately 1% Middle East revenue exposure could compress the H2 revenue ramp
- Net debt of $4.51B and $200M in notes maturing by August 2026 limit financial flexibility if the margin recovery is delayed even one quarter
Should You Invest in Concentrix Corporation?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CNXC stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Concentrix Corporation alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CNXC stock on TIKR for Free →
